Scope
ACG treats alcohol-associated liver disease and alcohol use disorder as linked conditions requiring integrated liver and addiction care. Sustained abstinence is central across the disease spectrum. The guideline separately addresses asymptomatic fibrosis, cirrhosis, alcohol withdrawal and acute alcohol-associated hepatitis, where severity, contraindications and early response determine treatment.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify and treat alcohol use disorder alongside liver disease
- Screen adults with a brief validated alcohol-use tool such as AUDIT-C, using a nonbiased approach at clinical encounters. Incorporate brief motivational intervention into care when both alcohol-associated liver disease and alcohol use disorder are present. [1]
- Offer integrated multidisciplinary liver and addiction care, combining behavioural treatment and, when suitable, medication for alcohol use disorder. Sustained abstinence is the most effective strategy for preventing progression and improving long-term outcomes at every stage. [1]
- Alcohol biomarkers can supplement history or questionnaires when the history is unavailable or unreliable; select the test for the suspected exposure window. They do not add useful information when the person already reports heavy recent use. [1]
- In compensated alcohol-associated liver disease, baclofen is a recommended AUD option. Acamprosate or naltrexone, and gabapentin or topiramate, are suggested alternatives; these recommendations do not establish routine use in decompensated disease. [1]
- If acamprosate is selected, adjust dosing for creatinine clearance 30–50 mL/min and avoid it below 30 mL/min. Avoid naltrexone in decompensated cirrhosis or liver failure and use caution with kidney disease; evidence for its use in acute alcohol-associated hepatitis is lacking. [1]
- Do not use disulfiram for AUD anywhere along the alcohol-associated liver-disease spectrum because of hepatotoxicity risk. [1]
- Distinguish alcohol withdrawal from hepatic encephalopathy, recognizing they can coexist. For severe withdrawal, use benzodiazepines cautiously with careful monitoring because they can precipitate or worsen encephalopathy; the source notes withdrawal severity scales are not validated in severe liver disease. [1]
Assess fibrosis and prevent further liver injury
- Use noninvasive fibrosis assessment in asymptomatic disease, initially FIB-4 and/or transient elastography. Biopsy is unnecessary for routine staging but may help resolve diagnostic uncertainty or competing diagnoses. [1]
- Interpret fibrosis tests in context: alcohol-related thrombocytopenia can distort FIB-4, while inflammation and elevated bilirubin can overestimate liver stiffness. Refer heavy drinkers with evidence of liver disease to an experienced liver provider and address addiction care. [1]
- Counsel against tobacco use with heavy alcohol use. Recommend alcohol avoidance in obesity and chronic hepatitis B or C; after gastric bypass, specifically counsel against heavy alcohol use. [1]
- Manage alcohol-associated cirrhosis similarly to cirrhosis of other causes, including ultrasound with or without alpha-fetoprotein every 6 months for HCC surveillance. Assess nutrition and vitamin deficiencies, and refer complications for transplant when medically indicated. [1]
Assess and support alcohol-associated hepatitis
- Suspect alcohol-associated hepatitis with heavy alcohol exposure and new or worsening jaundice. Clinical NIAAA criteria can establish probable disease without biopsy when no confounder exists; consider biopsy when the diagnosis is uncertain or criteria are unmet. [1]
- Use MELD >20 to identify severe alcohol-associated hepatitis and preferably manage these patients in hospital. The source’s treatment thresholds are based on original MELD, not MELD-Na; moderate disease at MELD ≤20 still carries meaningful morbidity and mortality. [1]
- Look actively for infection, including skin and line-related sources. Do not give prophylactic antibiotics universally to all hospitalized patients with severe hepatitis; absence of a routine prophylaxis indication must not prevent treatment of documented infection. [1]
- In hepatitis with malnutrition or inadequate oral intake, add oral nutritional supplements and proceed to enteral support if needs remain unmet. The source gives a goal of 35 kcal/kg/day and 1.2–1.5 g/kg/day protein, acknowledging extrapolation from critical-illness evidence. [1]
- Supplement common thiamine, vitamin B12 and zinc deficiencies in alcohol-associated hepatitis. Assess for Wernicke encephalopathy when mental status is abnormal rather than assuming all confusion is hepatic encephalopathy. [1]
Use corticosteroids with eligibility and response checks
- For severe hepatitis with MELD >20 and no contraindication, corticosteroid therapy is recommended. Benefit is greatest in the MELD 25–39 range; weigh risks especially carefully above 50 rather than treating all high scores identically. [1]
- Do not start corticosteroids with uncontrolled active infection, including untreated HBV, uncontrolled diabetes, gastrointestinal bleeding or severe renal failure. Treatment may become appropriate after adequate control or reversal of infection, bleeding and renal failure; monitor closely for new infection. [1]
- When eligible severe hepatitis is treated with corticosteroids, prednisolone is generally preferred; the source uses 40 mg/day for 4 weeks, with intravenous methylprednisolone 32 mg/day if oral treatment is impossible. Evaluate response early rather than automatically completing the course. [1]
- Assess corticosteroid response with the Lille score at day 4 or day 7. Stop corticosteroids for nonresponse, defined here as Lille >0.45. [1]
- ACG recommends intravenous N-acetylcysteine as an adjunct to corticosteroids in severe hepatitis and recommends against pentoxifylline. G-CSF and microbiome-based treatments have insufficient evidence for an established role; NAC is not presented as proven monotherapy. [1]
Consider transplant and continue addiction support
- Consider early transplantation for highly selected severe-hepatitis patients unresponsive to medical treatment and at high risk of death, according to local transplant protocols. Selection should not rely solely on an arbitrary sobriety duration; require comprehensive psychosocial and addiction evaluation. [1]
- Use relapse-risk scores only as adjuncts to the addiction team’s evaluation. After transplant, monitor alcohol use with self-report or biomarkers to enable early support and maintain multidisciplinary care; these scores do not reliably identify every high-risk individual. [1]
- For severe hepatitis unresponsive to corticosteroids, with ineligibility for early transplantation and at least 4 organ failures, the guideline considers palliative therapy appropriate. Preserve all these conditions when applying this statement. [1]
Limitations and use
- This selected adult summary does not reproduce complete diagnostic criteria, cirrhosis complication pathways, alcohol-withdrawal dosing protocols or all medication contraindications and interactions.
- The severe-hepatitis treatment thresholds were developed principally using original MELD; do not silently substitute a different MELD version. Selected corticosteroid doses do not override contraindication screening or response-based discontinuation.
- AUD drug recommendations specify compensated disease. Local authorization, renal function, concurrent medicines and specialist assessment remain necessary; this is not an opioid-use or pregnancy prescribing protocol.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Liver: Alcohol-Associated Liver Disease
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.